December 15, 2025: Study Shows that Zepbound May Not Reduce the Risk of Obesity-Related Cancers Earlier this year, researchers suggested that Zepbound, which many people take to lose weight, could lower someones risk of thirteen different obesity-related cancers
Tirzepatide clinical trials show that consistent meal timing and smaller portions optimize glycemic control and weight loss outcomes
The SURMOUNT-OSA study used tirzepatide in two phase 3 double-blind randomised placebo-controlled trials in obese adults with moderate-to-severe OSA
In summary, this trial confirmed a favourable riskbenefit profile of semaglutide 0.5 and 1.0 mg in the overall population as well as in Chinese patients with T2D in line with the results from other SUSTAIN trials
We conclude that in patients with severe disease and an important inflammatory component, a rapid response can be obtained with a multimodal, tailored approach that also includes treatment to repair and protect the skin barrier
This is often closely intertwined with mast cell activation syndrome (MCAS), where accumulated toxins and chronic oxidative stress cause mast cells to become hyper-reactive, constantly degranulating and releasing histamine and other inflammatory mediators into the bloodstream
